[1] Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J]. Hum Genet, 2007, 121(1): 23- 34. [2] Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response[J]. N Engl J Med,2011,364:1144-53. [3] Reiner MJ, Reiner AP, Gage BF, et a1. Effect of VKORCI haplotypes on transcriptional regulation and warfarin dose[J].N Engl J Med, 2005, 352:2285-2293. [4] Yang L, Ge W, Yu F, et al. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis[J]. Thrombosis Research, 2010,125(4): e159 - e166. [5] Schwarz U l, Ritchie M D, Bradford Y, et al.Genetic Determinants of Response to Warfarin during Initial Anticoagulation[J]. N Engl J Med,2008,358(10):999-1008. [6] Sanderson S, Emery J, Higgins J. CYP2C9 gene variants,drug dose,and bleeding risk in warfarin-treated patients:a HuGEnet systematic review and meta-analysis[J]. Genet Med, 2005,7(2):97-104. [7] Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation[J]. Circulation, 2007,116:2563-2570. [8] Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin[J]. Clin Pharmacol Ther,2008,84:326-331. [9] Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin- treated cohort supports genetic forecasting[J]. Blood, 2009,113: 784-792. [10] Huang SW,Chen HS,Wang XQ,et al.Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose:a prospective study in Chinese patients[J]. Pharmacogenetics and Genomics,2009,19(3):226-234. |